TY - JOUR
T1 - Addendum
T2 - Low-value approvals and high prices might incentivize ineffective drug development
AU - Prasad, Vinay
AU - McCabe, Christopher
AU - Mailankody, Sham
PY - 2018/12/1
Y1 - 2018/12/1
N2 - In hindsight, we realize that we could have been more precise when using the terms 'profit' and 'revenue' in our article 'Low-value approvals and high prices might incentivize ineffective drug development'. Total revenue is defined as the receipts from sales1. Profit is defined as the excess of the receipts from sales over the spending of a business during any period1. Hence, profit is the total revenue minus the costs of a business, over a given period. Profit calculations include credit transactions and asset revaluations as well as cash transactions and changes in the value of real assets1.
AB - In hindsight, we realize that we could have been more precise when using the terms 'profit' and 'revenue' in our article 'Low-value approvals and high prices might incentivize ineffective drug development'. Total revenue is defined as the receipts from sales1. Profit is defined as the excess of the receipts from sales over the spending of a business during any period1. Hence, profit is the total revenue minus the costs of a business, over a given period. Profit calculations include credit transactions and asset revaluations as well as cash transactions and changes in the value of real assets1.
UR - http://www.scopus.com/inward/record.url?scp=85056607571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056607571&partnerID=8YFLogxK
U2 - 10.1038/s41571-018-0120-1
DO - 10.1038/s41571-018-0120-1
M3 - Article
C2 - 30420734
AN - SCOPUS:85056607571
SN - 1759-4774
VL - 15
SP - 787
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 12
ER -